81 reports

The 2020-2025 World Outlook for Insulins and Anti-Diabetic Hormones and Synthetic Substitute Pharmaceuticals ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Antidiabetics
  • Hormone
  • Therapy
  • Demand

The 2019-2024 Outlook for Insulins and Anti-Diabetic Hormones and Synthetic Substitute Pharmaceuticals in China ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Antidiabetics
  • Hormone
  • Therapy
  • China
  • Demand

The 2019-2024 Outlook for Insulins and Anti-Diabetic Hormones and Synthetic Substitute Pharmaceuticals in India ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Antidiabetics
  • Hormone
  • Therapy
  • India
  • Demand

US Antidiabetics Drug Market Outlook 2022 ##.

  • Antidiabetics
  • Chronic Disease
  • Diabetes
  • Insulin
  • United States

RoW other antidiabetics market, by product, 2012 – 2020 (USD Million) List of Figures ##.

  • Antidiabetics
  • Therapy
  • United States
  • Forecast
  • Market Size

Coupled with a bad nutritional history and the fact that Indians are genetically more vulnerable to diabetes compared to other population groups, India’s struggle with diabetes is expected to be one of the biggest epidemics the country has ever witnessed.

  • Antidiabetics
  • Chronic Disease
  • Diabetes
  • India
  • Market Size
  • Forecast for Top Anti-diabetic Products
  • Forecast for Top Anti-diabetic Molecules

GLP-## ANALOGS DPP-IV INHIBITORS Incretin Mimetics THE TABLE BELOW DETAILS THE SALES OF THE ANTI-DIABETICS BY DRUG CLASS IN 2014.

  • Antidiabetics
  • United States
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Takeda Pharmaceutical Company Limited
  • APIDRA ASSUMPTIONS
  • PROVIDES A SWOT ANALYSIS OF SEMAGLUTIDE. TABLE 100: SEMAGLUTIDE SWOT ANALYSIS, 2016

CURRENTLY, MOST ANTIDIABETIC AGENTS ARE ME-TOO DRUGS POISED TO TACKLE PATIENT COMPLIANCE.

  • Antidiabetics
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • Chapter III

Pioglitazone hydrochloride is an antidiabetic medicine which is used in those people with type ## or non-insulin dependent diabetes (NIDDM).

  • Antidiabetics
  • China
  • Bayer AG
  • Beijing Taiyang Pharmaceutical Group
  • Eli Lilly & Co.

Datamonitor Healthcare Type ## Diabetes KOL Interview – US Overview In this discussion with a US KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

  • Antidiabetics
  • Therapy
  • Type 2 Diabetes
  • United States
  • Forecast

Datamonitor Healthcare Type ## Diabetes KOL Interview – Italy Overview In this interview with an Italian KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

  • Antidiabetics
  • Italy
  • Forecast

Datamonitor Healthcare Type ## Diabetes KOL Interview – UK Overview In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

  • Antidiabetics
  • Therapy
  • Type 2 Diabetes
  • United Kingdom
  • Forecast
  • Total Insulin Sensitizer Production and Demand (million Yuan)
  • CHAPTER IV DIABETES DRUGS PRODUCTION AND DEMAND

Pioglitazone hydrochloride is an antidiabetic medicine which is used in those people with type ## or non-insulin dependent diabetes (NIDDM).

  • Antidiabetics
  • China
  • GSK China Inc.
  • Novo Nordisk Pharmaceutical Co., Ltd.
  • Zhejiang Expressway Co., Ltd.

MARKET INSIGHTS TABLE OF CONTENTS ##.

  • Antidiabetics
  • Canada
  • North America
  • AgaMatrix, Inc.
  • AstraZeneca PLC

Japan Diabetes Market Report: 2019-2024 ## Preface ## Scope and Methodology ##. ## Objectives of the Study ##. ## Stakeholders ##. ## Data Sources ##. ##. ## Primary Sources ##. ##. ## Secondary Sources ##. ## Market Estimation ##. ##. ## Bottom-Up Approach ##. ##. ## Top-Down Approach ##. ## Forecasting Methodology ## Executiv

  • Antidiabetics
  • Diabetes
  • Japan
  • Demand
  • Market Size

CoMFA and CoMSIA studies onC-aryl glucoside SGLT## inhibitors as potential anti-diabetic agents.

  • Antidiabetics
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.
  • Johnson & Johnson
  • Total Insulin Sensitizer Production and Demand (million Yuan)
  • CHAPTER IV DIABETES DRUGS PRODUCTION AND DEMAND

The auto exports exceeded over ## million each year.

  • Antidiabetics
  • Diabetes
  • Insulin
  • China
  • Demand

KEY COMPANIES COVERED ##.

  • Antidiabetics
  • Western Europe
  • Forecast
  • Insulet Corporation
  • Medtronic, Inc.

Glucagon-like peptide-## (GLP-##) receptor agonists ##. ##. ##. ##.

  • Antidiabetics
  • Therapy
  • APAC
  • World
  • Market Size
  • CHAPTER V INSULIN MARKETS OUTLOOK

Most patients are treated only with diet modification and moderate exercise but some take anti-diabetic drugs, including insulin.

  • Antidiabetics
  • China
  • Demand
  • Market Size
  • Eli Lilly & Co.

## ## Phase II ## ## ## - ## Phase I ## ## - - ## Phase ## - - - - - IND/ CTA Filed ## - - - ## Preclinical ## ## - - ## Discovery - - - - ## ##% ##% ##% ##% Stage United States % of Pipeline in Preclinical Development Europe Japan China Global*

  • Antidiabetics
  • United States
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Japan Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics ## Preface ## Research Methodology ## Executive Summary ## Introduction ##. ## Overview ##. ## Key Industry Trends ## Diabetes Disease Overview ##. ## What is Diabetes?

  • Antidiabetics
  • Chronic Disease
  • Diabetes
  • Japan
  • Market Size

Around three decades ago, less than one percent of the Chinese adult population had diabetes.

  • Antidiabetics
  • Chronic Disease
  • Diabetes
  • China
  • Market Size

INTRODUCTION.............. ## ##.

  • Antidiabetics
  • China
  • India
  • World
  • Market Shares
  • ANTI-DIABETIC DRUG CLASSES: HISTORY OF DEVELOPMENT
  • HIGHLIGHTS THE VARIOUS ANTI-DIABETIC DRUG CLASSES AND THE FIRST APPROVED DRUG OF EACH CLASS.

PUBLICATIONS ON GLP-## AGONISTS: DISTRIBUTION BY MANY STUDIES HAVE BEEN PUBLISHED ON VARIOUS ANTI-DIABETIC DRUGS BELONGING TO THE GLP- ## AGONIST CLASS.

  • Antidiabetics
  • North America
  • United States
  • Boehringer Ingelheim GmbH
  • Sanofi S.A.

(Hong Kong) ##.

  • Antidiabetics
  • United States
  • World
  • Market Size
  • Supply

##.

  • Antidiabetics
  • Market Size
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Medtronic, Inc.
  • GLOBAL TYPE 2 DIABETES MARKET
  • UNPREDICTABLE OUTCOMES ON HUMAN DUE TO LACK OF PREDICTABLE ANIMAL MODELS

In January 2011, Eli Lilly and Boehringer Ingelheim entered into an agreement covering antidiabetic drugs.

  • Antidiabetics
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Sanofi S.A.

(USA) ##.

  • Antidiabetics
  • United States
  • World
  • Market Shares
  • Supply

Sweden ##.

  • Antidiabetics
  • Northern Europe
  • Western Europe
  • Forecast
  • Roche Group